Comparing the current results to its competitors, Sensei Biotherapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.67 %, recorded in the same quarter.
Sensei Biotherapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapidly advancing technologies, intense competition, and a strong focus on intellectual property. Its lead product candidate, PIKTOR, is described as having potential advantages including high potency, broad anti-tumor effects, selective PI3Kα inhibition, and synergistic activity with other therapies. Competitors include pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. These competitors may possess greater financial resources, established market presence, and expertise in research, development, manufacturing, clinical testing, regulatory approvals, reimbursement, marketing, and talent recruitment. Specific competitor products mentioned include sapanisertib and serabelisib, with sapanisertib used in pharmacokinetic modeling studies. The company also notes competition involving multi-node inhibitors and mutant-selective inhibitors targeting the PI3K/AKT/mTOR pathway. The acquisition of Faeth Therapeutics is part of the company’s strategic initiatives.
June 13, 2025
On June 13, 2025, Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology firm focused on pioneering therapeutics for cancer treatment, announced a significant corporate action: a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. This move, set to take effect at 5:00 p.m. Eastern Time on June 16, 2025, follows approval from the company’s stockholders during its Annual Meeting on May 21, 2025. The reverse stock split was ultimately decided upon by the Board of Directors, aiming to enhance the company s compliance with the Nasdaq Capital Market s minimum bid price requirement.Reverse stock splits, while commonly employed to improve a company’s stock pric...
May 23, 2024
NEWS HEADLINE: Sensei Biotherapeutics SNS-101 Shows Promising Clinical Activity in Phase 1 Dose Escalation StudySensei Biotherapeutics, a leading biotechnology company focused on the development of immunotherapies, has recently presented encouraging clinical data from its Phase 1 dose escalation study of SNS-101. The study demonstrated initial signs of promising clinical activity, marking a significant milestone in the quest for effective cancer treatments.SNS-101, a novel cancer-targeting therapy, was tested in a once every 3-week dosing regimen during the Phase 1 study. The results were highly encouraging, with initial signs of clinical activity observed. This represents a major breakthrough for Sensei Bi...
Publicly Traded Peers of Sensei Biotherapeutics Inc
Zymeworks Inc Share Performance
-12.04%
Over The Past 5 Days
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Sensei Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sensei Biotherapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
